Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 11,742 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level A Clear all
Not yet recruiting Not applicable Interventional

Laterality Training and Pain Drawings

NCT07078084
View directory record Official record
Conditions
Chronic Musculoskeletal Pain, Chronic Shoulder Pain, Chronic Knee Pain
Interventions
Laterality Training, Sham (No Treatment)
Behavioral · Other
Lead sponsor
Hawaii Pacific University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Moline, Illinois • Davenport, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158
View directory record Official record
Conditions
Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
Interventions
ABT-335, placebo, atorvastatin, ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
118
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 26, 2026, 2:09 PM EDT
Recruiting No phase listed Observational

Patient Registry of Blind Subjects With Sleep-related Problems

NCT01195558
View directory record Official record
Conditions
Sleep-wake Disorder in Blind Individuals
Interventions
Data collection on blindness and sleep problems
Other
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 26, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Lean Beef Consumption on Cardiometabolic Health and Gut Microbiome

NCT06433115
View directory record Official record
Conditions
Diet Intervention
Interventions
Lean (≥90%) Grass-Fed Beef, Lean (≥90%) Grain-Fed Beef, Plant-Based Meat
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 2:09 PM EDT
Not listed No phase listed Observational

HbA1c as an Early Serologic Marker for the Hemodynamic Progression of Stage A Heart Failure

NCT04450576
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Glycosylated hemoglobin
Diagnostic Test
Lead sponsor
Parkview Medical Center
Other
Eligibility
Not listed
Enrollment
200 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pueblo, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 26, 2026, 2:09 PM EDT
Recruiting Phase 1 Interventional

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

NCT07361562
View directory record Official record
Conditions
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Interventions
CGT4255
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

NCT03140527
View directory record Official record
Conditions
Healthy Volunteer, Cystic Fibrosis
Interventions
PTI-801, Placebo, PTI-808
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

Study of CPI-200 in Patients With Advanced Tumors

NCT03953742
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CPI-200
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Early Phase 1 Interventional Results available

Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents

NCT02726542
View directory record Official record
Conditions
NAFLD
Interventions
somatropin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 29 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 26, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

A Partnered Evaluation to Improve the Identification and Management of Functional Impairment and Frailty Among Older Veterans in Primary Care Settings

NCT06404970
View directory record Official record
Conditions
Functional Impairment, Frailty
Interventions
Screening intervention, Standard bundle of implementation strategies, Enhanced bundle of implementation strategies
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 26, 2026, 2:09 PM EDT
Terminated Phase 1 Interventional Results available

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

NCT02192541
View directory record Official record
Conditions
Neoplasms
Interventions
Ziv-Aflibercept, Ganetespib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 26, 2026, 2:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

NCT02661022
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SL-401 7 µg/kg/day, SL-401 9 µg/kg/day
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 26, 2026, 2:09 PM EDT
Terminated Phase 1 Interventional

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

NCT04311710
View directory record Official record
Conditions
Tumor
Interventions
ipilimumab, nivolumab, ENHANZE (rHuPH20)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hartford, Connecticut • Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)

NCT01954979
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Abatacept
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ETT Rotation During Nasal Fiberoptic Intubation

NCT02405546
View directory record Official record
Conditions
Dental Caries
Interventions
Pre-Rotated (Group R), No pre-rotation
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

NCT05896761
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions
Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Bakersfield, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Results available

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

NCT02530905
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SRP-4045, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 21 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Coffee Cherry Study

NCT04986956
View directory record Official record
Conditions
Effect of Drug
Interventions
Whole coffee cherry extract, Placebo
Dietary Supplement
Lead sponsor
Auburn University
Other
Eligibility
40 Years to 65 Years
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 26, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache

NCT03430531
View directory record Official record
Conditions
Post-Dural Puncture Headache, Sphenopalatine Ganglion Block
Interventions
Lidocaine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Phase 1 Interventional Results available

IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread

NCT01099631
View directory record Official record
Conditions
Cancer of the Liver, Liver Cancer, Hepatoma, Liver Neoplasms, Biliary Cancer
Interventions
Salmonella typhimurium
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Accuracy of Current Techniques in Quantifying Ketone Levels

NCT06909331
View directory record Official record
Conditions
Placebo - Control, Exogenous Ketone Salt
Interventions
Exogenous ketone salt, Placebo drink solution
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

NCT00782379
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 26, 2026, 2:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

NCT05765396
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
Interventions
imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 26, 2026, 2:09 PM EDT
Completed Not applicable Interventional Results available

PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors

NCT01567462
View directory record Official record
Conditions
Bladder Cancer
Interventions
Monopolar electrocautery loop in Transurethral resection of bladder tumors, PK Button Vaporization Electrode in transurethral resection of bladder tumors
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 26, 2026, 2:09 PM EDT